INTRODUCTION
the national incidence rate had dropped steadily from 2.24/100,000 population in 2000 to 0.41/100,000 in 2013 (Graph 2). The incidence rate of HBV in Malaysia from 1990 to 2013 demonstrated a steady decrease from 1990 to 1997 due to the universal vaccination of infants, which commenced in 1989, and various control programs (Graph 3). In 1998, however, a sharp increase in reported cases was noted due to the inclusion of mandatory testing of all foreign workers who had arrived in Malaysia. The decrease trend followed after 2000, which rose again from 2010, as government has implemented the rule that all cases of hepatitis B be reported to hospitals. injection. Yet awareness about hepatitis C in Malaysia is low. 9 In 2000, there were 550 reported cases of hepatitis C, with an incidence rate of 2.5/100,000 population; in 2004 there were 741 cases with an incidence rate of 2.9/100,000 population, and in the year 2013 the incidence rate became 6.77/100,000, which reflects the overgrown disease burden (Graph 4). 2 The most common genotypes found in Malaysia are genotype 3 and 1. Many studies showed that over the past 15 years this genotype distribution remain unchanged in Malaysia. The estimated prevalence in females is considerably lower than among males, and the estimated number of HCV antibody-positive male Malays are much higher (84%) than the numbers for the other 2 ethnicity groups. The main modes of HCV transmission identified were parenteral drug use (85%), transfusion (3%), and/ or dialysis.
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FUTURE
According to ministry records, 5% of Malaysians suffer from hepatitis B, while 2% carry HCV. Statistics also show that more than 80% of hepatitis B and C patients are aged between 25 and 55 years. The nationwide HBV vaccination program for children was introduced in 1989, which managed to reduce the rate of infection among Malaysians to 0.3% (exceeding WHO's target of 1%). But the disease burden will still remain high for some time as the infected people are getting older and living longer.
The HCV-related disease burden is already high and is forecast to rise steeply over the coming decades under current levels of antiviral treatment. Although the current treatment practice is estimated to avert a cumulative total of 2,200 deaths from Liver cirrhosis (LC) or HCC, a cumulative total of 63,900 HCV-related deaths are projected by 2039 with a predicted 2,002 and 540 new decompensated cirrhosis (DC) cases and new HCC cases respectively. Increased governmental resources to improve HCV screening and treatment rates and to reduce transmission are essential to address the high projected HCV disease burden in Malaysia. 12 
CONCLUSION
In summary, the prevalence of cirrhosis and the incidence of end-stage liver disease and death due to chronic HCV infection are projected to rise steeply over the next 25 years. A detailed economic analysis is required to estimate the implications of these burden projections for future public health expenditure associated with HCV infection. Increasing HBV and HCV screening and treatment rates, together with intensive efforts to reduce transmission (e.g., through vaccination, stepped-up harm reduction, education, and other prevention initiatives), would appear essential to address the existing HBV and predicted high HCV disease burden in Malaysia.
